LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been assigned an average recommendation of “Moderate Buy” from the eight analysts that are presently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $100.20.

Several equities research analysts have commented on the stock. Zacks Research raised shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a report on Friday, November 7th. Roth Capital reissued a “buy” rating and issued a $108.00 price objective on shares of LeMaitre Vascular in a report on Wednesday, November 5th. Wells Fargo & Company lowered their target price on LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating on the stock in a research note on Friday, November 7th. Weiss Ratings upgraded LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday. Finally, Wall Street Zen downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Saturday, December 6th.

LeMaitre Vascular Price Performance

Shares of NASDAQ LMAT opened at $85.27 on Friday. LeMaitre Vascular has a 52 week low of $71.42 and a 52 week high of $105.55. The business’s 50 day moving average price is $86.26 and its 200 day moving average price is $87.18. The company has a quick ratio of 11.45, a current ratio of 13.58 and a debt-to-equity ratio of 0.44. The firm has a market cap of $1.93 billion, a P/E ratio of 36.75, a P/E/G ratio of 2.10 and a beta of 0.68.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $0.62 EPS for the quarter, beating the consensus estimate of $0.57 by $0.05. The business had revenue of $61.05 million during the quarter, compared to analysts’ expectations of $62.18 million. LeMaitre Vascular had a net margin of 22.14% and a return on equity of 14.06%. The business’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.49 EPS. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS and its Q4 2025 guidance at 0.640-0.690 EPS. On average, sell-side analysts expect that LeMaitre Vascular will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, December 4th. Investors of record on Thursday, November 20th were issued a dividend of $0.20 per share. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. LeMaitre Vascular’s dividend payout ratio is 34.48%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LMAT. Tudor Investment Corp ET AL purchased a new stake in shares of LeMaitre Vascular during the 3rd quarter worth about $6,056,000. CIBC Bancorp USA Inc. acquired a new position in LeMaitre Vascular in the 3rd quarter worth about $799,000. Advisory Services Network LLC acquired a new position in LeMaitre Vascular in the 3rd quarter worth about $98,000. PharVision Advisers LLC purchased a new position in LeMaitre Vascular during the third quarter worth approximately $355,000. Finally, Verition Fund Management LLC grew its holdings in LeMaitre Vascular by 136.2% in the third quarter. Verition Fund Management LLC now owns 16,907 shares of the medical instruments supplier’s stock valued at $1,480,000 after purchasing an additional 9,750 shares during the period. Hedge funds and other institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.